VKTX logo

Viking Therapeutics (VKTX) Company Overview

Profile

Full Name:

Viking Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 28, 2015

Indexes:

Not included

Description:

Viking Therapeutics is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. They aim to create new treatments for conditions like obesity and diabetes by advancing their drug candidates through clinical trials and research.

Events Calendar

Earnings

Next earnings date:

Apr 24, 2025

Recent quarterly earnings:

Feb 5, 2025

Recent annual earnings:

Feb 5, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 13, 25 Scotiabank
Sector Outperform
Feb 7, 25 Maxim Group
Buy
Feb 7, 25 Citigroup
Neutral
Feb 7, 25 B. Riley Securities
Buy
Feb 6, 25 Raymond James
Strong Buy
Feb 6, 25 Piper Sandler
Overweight
Feb 6, 25 HC Wainwright & Co.
Buy
Jan 17, 25 HC Wainwright & Co.
Buy
Jan 10, 25 HC Wainwright & Co.
Buy
Jan 8, 25 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Viking Therapeutics?
  • Does Viking Therapeutics pay dividends?
  • What sector is Viking Therapeutics in?
  • What industry is Viking Therapeutics in?
  • What country is Viking Therapeutics based in?
  • When did Viking Therapeutics go public?
  • Is Viking Therapeutics in the S&P 500?
  • Is Viking Therapeutics in the NASDAQ 100?
  • Is Viking Therapeutics in the Dow Jones?
  • When was Viking Therapeutics's last earnings report?
  • When does Viking Therapeutics report earnings?
  • Should I buy Viking Therapeutics stock now?

What is the ticker symbol for Viking Therapeutics?

The ticker symbol for Viking Therapeutics is NASDAQ:VKTX

Does Viking Therapeutics pay dividends?

No, Viking Therapeutics does not pay dividends

What sector is Viking Therapeutics in?

Viking Therapeutics is in the Healthcare sector

What industry is Viking Therapeutics in?

Viking Therapeutics is in the Biotechnology industry

What country is Viking Therapeutics based in?

Viking Therapeutics is headquartered in United States

When did Viking Therapeutics go public?

Viking Therapeutics's initial public offering (IPO) was on April 28, 2015

Is Viking Therapeutics in the S&P 500?

No, Viking Therapeutics is not included in the S&P 500 index

Is Viking Therapeutics in the NASDAQ 100?

No, Viking Therapeutics is not included in the NASDAQ 100 index

Is Viking Therapeutics in the Dow Jones?

No, Viking Therapeutics is not included in the Dow Jones index

When was Viking Therapeutics's last earnings report?

Viking Therapeutics's most recent earnings report was on Feb 5, 2025

When does Viking Therapeutics report earnings?

The next expected earnings date for Viking Therapeutics is Apr 24, 2025

Should I buy Viking Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions